aspirin / Generic mfg. - LARVOL DELTA

Chemoprevention of Gastrointestinal Cancers: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials and Cohort Studies. (PubMed, Clin Transl Sci) - "Seven inverse associations were graded as either high quality (celecoxib and colorectal adenomas, (N = 4)) or moderate (aspirin and colorectal adenomas, (N = 2) and H-pylori eradication and gastric cancer (N = 1)). This review suggests that the associations with the most consistent empirical evidence were confined to those targeting the well-established risk factors of gastrointestinal cancer progression. Despite the limited established evidence, the inverse associations observed between metformin and colorectal, esophageal, and gastric cancers, as well as between statins and HCC and gastric cancer, merit further research."

Journal • Review • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

First-trimester screening for pre-eclampsia (PubMed, Ugeskr Laeger) - "This review describes that low-dose acetylsalicylic acid can reduce the risk of preterm pre-eclampsia in high-risk pregnant women if treatment is started before the 16th week of pregnancy...The screening has been validated internationally and in Denmark. In 2025, a national implementation project will be initiated to evaluate the effectiveness of a change in screening strategy in Denmark."

Biomarker • Journal • Review • Gynecology

Why low-dose aspirin remains an important antiplatelet in the management of chronic coronary syndromes. (PubMed, Expert Rev Cardiovasc Ther) - "Low-dose aspirin has the highest recommendations in international guidelines for patients with chronic coronary syndromes (CCS), including a lifelong recommendation in patients post vascular interventions and those without prior myocardial infarction or revascularization but with evidence of significant obstructive coronary artery disease.P2Y12 inhibitors - including clopidogrel, ticagrelor, and prasugrel - have recently been explored as an alternatives to low-dose aspirin in patients with CCS, with various trials comparing their efficacy and safety to aspirin. Furthermore, P2Y12 inhibitors lack the evidence for long-term safety and efficacy that are associated with low-dose aspirin. We feel that low-dose aspirin remains a cornerstone therapy in the management of patients with CCS."

Journal • Review • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

Impact of antithrombotic medications on postprocedural outcomes of percutaneous endoscopic gastrostomy: a US Collaborative Network study. (PubMed, Eur J Gastroenterol Hepatol) - "These findings suggest that while anticoagulant use increases the risk of minor post-PEG bleeding, it does not lead to a higher incidence of severe bleeding. Additionally, the continuation of DAPT was not associated with statistically significant increase in bleeding risk. This study provides valuable insights into the management of antithrombotic therapy in patients undergoing PEG."

Journal

Does Aspirin Increase Risk of Bleeding in Patients Undergoing Skin Lesion Excision: A Systematic Review and Meta-Analysis. (PubMed, Plast Reconstr Surg Glob Open) - "Moderate severity bleeding (1629 procedures included) OR 0.92 (0.46-1.81), infection OR 0.60 (0.28-1.28), and wound dehiscence OR 0.92 (0.41-2.06) effect size results did not attain statistical significance. Our analysis identified a statistically significant increase in postoperative bleeding risk for patients taking aspirin and undergoing cutaneous surgery."

Journal • Retrospective data • Hematological Disorders • Infectious Disease • Oncology

Pituitary apoplexy in a patient on antiplatelet therapy: A case report. (PubMed, Exp Ther Med) - "The present study reported the case of a 45-year-old male who experienced intermittent headaches and progressive right-sided visual deterioration over two months, with acute worsening in the preceding 6 h. The patient's medical history included coronary stent implantation and the patient had been on enteric-coated aspirin therapy for ~4 months...At the 6-month follow-up, the patient exhibited complete recovery with no evidence of tumor recurrence on imaging. This case highlights the importance of timely diagnosis and surgical intervention in achieving favorable outcomes in pituitary apoplexy and serves as a reminder for clinicians to consider the risk of hemorrhage in patients on long-term antiplatelet therapy."

Journal • Hematological Disorders • Oncology • Ophthalmology • Pain • Pituitary Gland Carcinoma

The effect of aspirin on aneurysm wall enhancement: A study in rabbits and humans. (PubMed, Interv Neuroradiol) - "A total of 99 patients with 120 UIAs were included in the HR-MRI analysis of UIAs. UIAs exposed to ASA (22/120) had significantly lower median AWE than those that were not exposed (0.60 vs 0.72, p = 0.032).ConclusionASA therapy is associated with an objective reduction in AWE, suggesting a potential role in lowering the risk of aneurysm rupture."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Inflammation • Subarachnoid Hemorrhage • Vascular Neurology • CD68 • ELANE

Ischemic Stroke in a 2-Year-Old Male as a Presentation of Acute Promyelocytic Leukemia (ASPHO 2025) - "Once he obtained platelet recovery, he was started on enoxaparin while undergoing therapy...He has since been transitioned to aspirin and recently completed Consolidation #2... The case described above is unique given the young age of the patient and the presentation of APML with ischemic stroke without DIC."

Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Ischemic stroke • Leukemia • Oncology • Pediatrics • Thrombosis • PML

Moyamoya Syndrome in Patients With Trisomy 21 and Acute Lymphoblastic Leukemia: A Case Series (ASPHO 2025) - "Prophylactic enoxaparin was administered through delayed intensification and platelets were maintained >20,000/uL...She was on acetylsalicylic acid (ASA), which was held during induction and for platelet count <50,000/uL... This series highlights the need to remain cognizant of MMS in our patients with T21 and ALL, particularly in those with neurologic changes. These patients need individualized treatment balancing the risk of thrombosis due to MMS and a prothrombotic state as well as bleeding due to thrombocytopenia and antiplatelet therapy or anticoagulation."

Clinical • Acute Lymphocytic Leukemia • Cardiovascular • CNS Disorders • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Thrombocytopenia • Thrombosis • Vascular Neurology

Eptifibatide bolus dose postductal stenting intervention: A single-center experience. (PubMed, Ann Pediatr Cardiol) - "Oral antiplatelet drugs like aspirin have erratic and inconsistent absorption and antiplatelet effects in critically ill neonates. Dosing considerations should include age and renal function. Randomized trials are warranted to establish efficacy and compare with current anticoagulation practices."

Journal • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

Preparation and evaluation of oral enteric sustained-release liquid formulations of aspirin. (PubMed, Nanomedicine (Lond)) - "In vivo intestinal absorption and pharmacokinetic studies in rats demonstrated that AS-PLGA-EL@NPs enhanced drug absorption, prolonged drug release, and showed higher bioavailability compared to conventional enteric-coated tablets. The development and preparation of an oral enteric sustained-release nanoparticle delivery system for aspirin has the potential to serve a broader population, with promising applications in various therapeutic contexts."

Journal

Caffeine modulates immunoproteasome activity and content in colorectal adenocarcinoma cells. (PubMed, Biochimie) - "Using previously obtained reporter colorectal cancer cell lines, we tested how commonly used compounds including ibuprofen, acetylsalicylic acid, vitamin C, caffeine and others, affect immunoproteasome expression. Caffeine did not affect the degradation of immunoproteasomes by autophagy. Obtained results uncover novel biological effects of caffeine, our data might help to optimize existing and develop new strategies for the treatment of colorectal cancer and several autoimmune diseases."

Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Immunology • Oncology • Solid Tumor

Impact of Central Event Adjudication on the PLATO Trial Results. (PubMed, Rev Cardiovasc Med) - "This study aimed to determine the impact of central adjudication of site-reported events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in addition to aspirin within the frame of indication-seeking The PLATelet Inhibition and Clinical Outcomes (PLATO) trial. Central adjudication in the PLATO trial was delayed and impacted the primary endpoint by inflating the ticagrelor benefit, resulting in drug approval. The regulatory authorities should consider independent audits when unblinding is suspected in the indication-seeking clinical trials."

Journal • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction • Myocardial Ischemia

Low-dose ASA therapy does not alter core or skin temperature during hot-dry or warm-humid heat stress (PSU HEAT project). (PubMed, Physiol Rep) - "Nearly 40% of US adults over the age of 50 use aspirin (ASA) therapy for the primary or secondary prevention of cardiovascular disease...Low-dose ASA attenuated FBF and forearm vascular conductance (all p ≤ 0.04) but had no effect on Tc or Tsk in either environment. In conclusion, low-dose ASA attenuates the skin blood flow response during minimal activity heat stress in both dry and humid environments but does not alter Tc."

Clinical • Journal • Cardiovascular

Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study. (PubMed, Diabetes Res Clin Pract) - P4 | "Very-low-dose rivaroxaban and low-dose aspirin in T2DM patients significantly inhibit in vivo platelet function, TG and isoprostane formation. EudraCT Number: 2019-000610-10."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Inflammation • Metabolic Disorders • Peripheral Arterial Disease • Thrombosis • Type 2 Diabetes Mellitus

Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Taichung Veterans General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement. (PubMed, Heart) - P | "Among patients who underwent TAVR, 1.7% of patients experienced upper GI bleeding within 1 year of discharge. Major or life-threatening upper GI bleeding was associated with an increased risk of all-cause and cardiovascular mortality."

Journal • Atrial Fibrillation • Cardiovascular • Gastroenterology • Hemophilia

Conditional Survival Analysis and Risk Factors for Mortality in Patients with Chronic Limb-Threatening Ischemia. (PubMed, J Vasc Surg) - "Conditional survival improves in CLTI patients who survive beyond the first-year post-diagnosis, yet 5-year mortality remains high. This finding highlights the substantial early mortality risk in CLTI patients but also indicates that surviving the first year significantly improves subsequent survival odds. Several factors contribute to early mortality risk in CLTI, many of which are modifiable, underscoring the importance of targeted interventions in this high-risk population."

Journal • Cardiovascular • Coronary Artery Disease • Heart Failure • Oncology • Peripheral Arterial Disease

Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies. (PubMed, Ann Rheum Dis) - "The enhanced biosynthesis of TXA2 in platelets, with a minor contribution from leukocytes, may contribute to the increased cardiovascular risk associated with JAKis. Low-dose aspirin may offer a protective effect, warranting further investigations."

Adverse events • Journal • Preclinical • Ankylosing Spondylitis • Cardiovascular • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Seronegative Spondyloarthropathies • Spondylarthritis • Systemic Lupus Erythematosus

Characteristics of heart failure patients treated in primary care - a 20-year perspective of real-world data. (HEART FAILURE 2025) - "A decline was observed in the utilisation of angiotensin-converting enzyme inhibitors, mineralocorticoid receptor antagonists, aspirin and diuretics, while a concomitant rise was evident in the use of beta-blockers and angiotensin receptor antagonists. Moreover, new therapies have emerged (sacubitril/valsartan, SGLT2 inhibitors)... Although the mean age did not change, the profile of HF patients treated in primary care in Poland changed significantly over the last 20 years, with different comorbidity distribution and more HF diagnosed with preserved ejection fraction. Nowadays patients are more likely to receive invasive treatment (PCI, ICD, pacemaker). Although many changes have been observed in the pharmacotherapy regimens, the newer therapies are still underused."

Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Myocardial Infarction

Clinical predictors of one-year mortality in STEMI patients across the spectrum of LVEF: insights from a large multicenter registry. (HEART FAILURE 2025) - "Prescriptive trends at discharge differed markedly, with patients in the reduced LVEF less prone to receive beta-blockers, statins, ACE inhibitors or ARBs and aspirin, but more frequently ticagrelor and oral anticoagulants. One-year mortality in STEMI patients is influenced by distinct clinical and therapeutic factors based on LVEF category. Age and malignancy were consistent predictors across groups, with radial access and DES protective for patients with reduced LVEF. These findings underscore the importance of personalized management strategies tailored to LVEF profiles to improve outcomes."

Clinical • Cardiovascular • Myocardial Infarction

Adults with fontan circulation: insights from a Portuguese adult congenital heart disease center (HEART FAILURE 2025) - "Medical therapy included ACE inhibitors (46%), spironolactone (35%), SGLT2 inhibitors (24%), beta blockers (30%), diuretics (19%), aspirin (49%), anticoagulation with warfarin (22%) or DOAC (24%).Median follow-up duration was 6 years since transition to ACHD clinic, with regular multidisciplinary evaluations. Adult Fontan patients represent a heterogeneous group with diverse anatomical anomalies, comorbidities and clinical trajectories. This single-center experience highlights the importance of individualized long-term follow-up to address unique clinical needs and improve outcomes."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Changes of iron status during acutely decompensated heart failure hospitalisation and its association with adverse events after discharge (HEART FAILURE 2025) - "The Worsened-ID group had statistically higher proportion of patients receiving low-dose aspirin (33%) and HIF-PH inhibitors (17%) at discharge, while no significant differences in other HF medications... New onset of ID using new criteria during hospitalisation was associated with poorer prognosis after discharge in patients with ADHF."

Adverse events • Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Association between congestion and aspirin resistance in patients with chronic coronary syndrome (HEART FAILURE 2025) - "Сongestive heart failure could potentially be the cause of reduced bioavailability for ASA and leads to aspirin resistance, especially its enteric coated form."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Design, Synthesis, Biological Evaluation, and In Silico Study of Aspirin-Sulfonamide Hybrids as Potential Anticancer Agents. (PubMed, Arch Pharm (Weinheim)) - "Molecular docking analysis and COX-2 inhibition assay indicated that hybrid 3k likely exerts its anticancer effects through the inhibition of COX-2 protein. These findings underscore the potential of hybrid 3k as a novel therapeutic agent for non-small-cell lung cancer and its contribution to expanding the antitumor scope of aspirin."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor